Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to “Buy” at StockNews.com

StockNews.com upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a hold rating to a buy rating in a report released on Saturday.

AMPH has been the subject of several other research reports. Needham & Company LLC reaffirmed a hold rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler decreased their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an overweight rating for the company in a research report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $63.00.

Amphastar Pharmaceuticals Stock Performance

Amphastar Pharmaceuticals stock opened at $44.96 on Friday. The business has a 50 day moving average of $40.60 and a 200-day moving average of $43.56. Amphastar Pharmaceuticals has a 1 year low of $36.56 and a 1 year high of $65.92. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.18 and a quick ratio of 1.72. The company has a market capitalization of $2.20 billion, a P/E ratio of 15.56, a P/E/G ratio of 0.75 and a beta of 0.79.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, Director Richard K. Prins sold 17,101 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $43.07, for a total transaction of $736,540.07. Following the completion of the sale, the director now owns 33,971 shares of the company’s stock, valued at approximately $1,463,130.97. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Richard K. Prins sold 17,101 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $43.07, for a total transaction of $736,540.07. Following the completion of the sale, the director now owns 33,971 shares of the company’s stock, valued at approximately $1,463,130.97. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $41.40, for a total transaction of $124,200.00. Following the sale, the director now directly owns 78,409 shares of the company’s stock, valued at approximately $3,246,132.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,479 shares of company stock valued at $1,484,022. 27.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Large investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 7.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 379,480 shares of the company’s stock worth $23,471,000 after purchasing an additional 27,102 shares in the last quarter. Epoch Investment Partners Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 348.7% in the 4th quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company’s stock worth $36,648,000 after purchasing an additional 460,473 shares in the last quarter. TD Asset Management Inc lifted its holdings in shares of Amphastar Pharmaceuticals by 449.0% in the 4th quarter. TD Asset Management Inc now owns 793,559 shares of the company’s stock worth $49,082,000 after purchasing an additional 649,001 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 870.9% in the 4th quarter. Victory Capital Management Inc. now owns 237,474 shares of the company’s stock worth $14,688,000 after purchasing an additional 213,014 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 35.1% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock worth $4,937,000 after purchasing an additional 29,182 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.